Latest News & Features
Refine Search
Biotechnology
For those involved in the development of biological drugs, the prospects of getting what would seem to be a ‘fair reward’ may not have improved much, says Jaap Mannaerts. 20 June 2014
Americas
The rate of development in the biotech sector means revisions to the patent guidelines are more needed than ever, says Marisa Moura Momoli. 20 June 2014
Biotechnology
The exclusion from patentability of certain cells derived from human embryos is a reflection of the EPO’s increasingly restrictive stance, say Franz-Josef Zimmer and Markus Grammel. 20 June 2014
Americas
Obviousness-type double patenting is a serious consideration that patent owners should keep in mind during the examination of an application or in performing due diligence on a patent portfolio, says MaryAnne Armstrong. 20 June 2014
Americas
More than 15,000 life sciences industry professionals will arrive in San Diego this month for the annual BIO International Convention. LSIPR looks at some of the most interesting sessions, and talks to a couple of speakers. 20 June 2014
Asia-Pacific
Amendments to SIPO’s guidelines for the examination of utility patents may help stop the proliferation of ‘junk’ utility models in China. Wolfgang Bublak and Yingkun Brunner report. 20 June 2014
Genetics
The realm of patent eligibility under 35 USC §101 has become more confusing, with the introduction of a possible new definition of admissibility after a decision on Dolly the sheep. Nabeela Rasheed reports. 20 June 2014
Big Pharma
Andrew Wright and Tom Harding investigate how a decision by the EPO’s Board of Appeal may extend the opportunities for protection by second medical use claims. 20 June 2014
Americas
Acting against infringers can involve the pharmaceutical regulatory framework and civil law as well as following the more usual pathways, says José R. Trigueros. 20 June 2014
Generics
There is no uniform interpretation of the scope of the Bolar exemption in Europe, but a CJEU opinion harmonising the issue may be on the way, says Rafal Witek. 20 June 2014